How Value Analysis Committees’ Lines of Questioning Can Directly Affect Value Equation Outputs

By AHRMM

John Kelty from W.L. Gore & Associates discusses how value analysis committees can determine a medical devices value when evaluating new products. 

Related Resources

Case Studies
Leading Practice: Reduction or Elimination of HAPU - Nexera
The following leading practice describes methods used to reduce Hospital Acquired Pressure Ulcers (HAPU).
Case Studies
Leading Practice: Reduction or Elimination of HAPU - University of Virginia Health System
AHRMM is developing a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a
Case Studies
Leading Practice: Reduction of Costs Related to Blood Products and Services - University of Pittsburgh Medical Center
AHRMM is offering a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a
Case Studies
Leading Practice: Reduction or Elimination in Hospital Acquired NPU - Terrebonne General Medical Center
AHRMM is developing a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a
Case Studies
Leading Practice: Reduction or Elimination of CAUTI - Blue.Point Supply Chain Solutions
AHRMM is offering a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a
Letter/Comment
The Official Comment of AHRMM to the United States Department of Health and Human Services Food and Drug Administration (FDA) regarding Unique Device Identification for Medical Devices Docket No. FDA-2011-N-0090
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Fo